Multikinase Inhibitor Motesanib Effects Alone and Combined with a Selective COX-2 Inhibitor in Colorectal Cancer Cells

Colorectal cancer (CRC) is a common solid tumor and it is a leading cause of cancer related death especially in developed countries (Center et al., 2009). About 500,000 deaths are reported per year worldwide due to CRC. Environmental factors, dietary habits, inflammatory bowel disease, age, male sex, and hereditary syndromes are a higher risk in the development of this disease (Chu, 2012). Improvements in screening and staging and also advances in surgery and therapy have enhanced the survival of patients. However CRC is still an important cause of cancer related death. Research groups are focused on understanding the risk factors, molecular biology, and genetics of CRC and also developing new drugs and drug combinations for the management of this deadly disease (van de Velde et al., 2014). Uncontrolled growth of the tumor and metastasis are main causes of death in patients with cancer. Angiogenesis plays a critical role in the progression of cancer and many proangiogenic factors are involved in this process. Therefore inhibiting tumor neovascularization by inhibiting the activity of these proangiogenic factors has been important for cancer treatment. Angiogenesis is mediated by interaction of multi factors including cytokines and angiogenic growth factors such as vascular